Mumbai-based pharma firm Encube Ethicals has filed for a ₹3,000 crore IPO. The offering is entirely an offer for sale by promoters and Quadria Capital, meaning the company will not receive fresh funds. Investors should note that while the business shows strong growth in revenue and profit, this issue represents an exit strategy for existing shareholders rather than capital expansion.
Encube Ethicals, a pharmaceutical formulations company based in Mumbai, has moved forward with its plans for a public market debut by filing draft papers with the Securities and Exchange Board of India. The company intends to raise ₹3,000 crore through an initial public offering. Unlike many IPOs that aim to raise money for new projects or debt reduction, this transaction is structured entirely as an offer for sale. This means all proceeds from the shares sold will go directly to existing shareholders, and the company itself will not receive any capital from this offering.
The selling shareholders include promoter Mehul Madhusudan Shah, who plans to offload shares worth approximately ₹2,000 crore, and Frontier Investment Holdings, an entity backed by Quadria Capital, which intends to sell shares valued at ₹1,000 crore. Following the sale, these major stakeholders will reduce their current holdings of 80.63 percent and 15.02 percent respectively.
Operational Scale and Market Reach
Encube Ethicals focuses on manufacturing pharmaceutical products with a strong emphasis on global markets. It operates two production facilities in Goa and Indore with a combined capacity of over 15,600 metric tonnes. The company’s Goa plant is particularly significant, as it holds approvals from major international regulators, including the US Food and Drug Administration and the Japanese PMDA. These certifications allow the company to export products to highly regulated global markets.
The company serves more than 160 clients through its contract development and manufacturing organization (CDMO) business. Its revenue is spread across three main areas: global generics, which contributed 47 percent of revenue in fiscal year 2026; CDMO services, contributing 42 percent; and India branded formulations, which accounted for 9 percent. With global clients making up 64 percent of its business, the firm relies heavily on export demand.
Financial Context and Investor Monitorables
For the fiscal year ending March 2026, Encube Ethicals reported a net profit of ₹437 crore, marking a 74.8 percent increase compared to the previous year. Revenue also grew by 37.5 percent to ₹1,848.7 crore. While these figures indicate strong recent performance, investors often look beyond top-line and bottom-line growth when evaluating a company that is primarily an exporter.
One of the primary factors for potential shareholders to monitor is the competitive nature of the global generic and topical pharmaceutical market. As a company with significant capacity, its financial health is closely tied to its ability to maintain high utilization rates at its manufacturing plants and manage pricing pressures in competitive international markets. Because this is an offer for sale, there is no new money coming into the business to fund future growth or debt reduction. Investors may want to track how the management plans to sustain its recent profit trajectory without the direct infusion of fresh capital from the IPO proceeds.